Scholar Rock Holding dividends
SRRK dividends
| Ex-dividend | Amount | Yield | Pay date | ||||
|---|---|---|---|---|---|---|---|
This company doesn't provide dividends. | |||||||
Scholar Rock is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Our most advanced product candidate, SRK-015, a selective first-in-class inhibitor of the activation of the growth factor myostatin in skeletal muscle, is currently in development for the treatment of spinal muscular atrophy, or SMA. We have successfully completed a Phase 1 clinical trial in healthy volunteers and initiated a Phase 2 proof-of-concept trial (named TOPAZ) in patients with later-onset (Type 2 and Type 3) SMA in the second quarter of 2019. In addition, we initiated the DRAGON Phase 1 clinical trial for our second product candidate, SRK-181, a highly specific inhibitor of latent TGFβ1 activation, in patients with locally advanced and metastatic solid tumors in the first quarter of 2020. We believe SRK-181 has the potential to render resistant solid tumors vulnerable to immune checkpoint inhibitors such as anti-PD1/PDL1 therapies and drive tumor regression through combination therapy.
Learning section - What Is a Dividend?
A dividend is the distribution of reward from a portion of the company's earnings and is paid to a class of its shareholders. Dividends are decided and managed by the company's board of directors, though they must be approved by the shareholders through their voting rights